Home › NDC Lookup › Ingredients › Methylprednisolone › 68001-0624-01
methylprednisolone 4 mg Tablet, 21-count — NDC 68001-0624-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

methylprednisolone 4 mg Tablet, 21-count — NDC 68001-624-01 (Billing 68001-0624-01)

by BluePoint Laboratories · 1 BLISTER PACK in 1 CARTON / 21 TABLET in 1 BLISTER PACK

This is a package of 21 tablets of methylprednisolone 4 mg Tablet from BluePoint Laboratories, marketed since May 2025 and currently FDA-listed; retail pharmacies pay about $0.1361 per tablet (NADAC). It is this product's only package size.

NDC 68001-0624-01
🏷️ FDA NDC (as labeled) 68001-624-01 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Methylprednisolone (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jan 15, 2026 — Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil. (Greenstone Llc) · FDA recall D-0299-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 68001-624-01
Product NDC 68001-624
11-digit billing NDC 68001062401
NCPDP billing unit EA — each (per item)
RxCUI 259966, 762675
UNII X4W7ZR7023
Application # ANDA206751
SPL Set ID 7092df48-4904-4047-9916-e585417a216f
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2025-05-01
Route ORAL
Dosage form TABLET
Substance METHYLPREDNISOLONE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 2210003000B705
GCN Seq No 045311
GCN 37499
HICL code 002877
Ingredient (HICL) Methylprednisolone
HIC1 code P
Therapeutic class — broad (HIC1) Endocrine System
HIC2 code P5
Therapeutic class — intermediate (HIC2) Adrenocortical Hormones
HIC3 code P5A
Therapeutic class — specific (HIC3) Glucocorticoids
AHFS code 68:04.00.00
AHFS class Adrenals
FDB label name METHYLPREDNISOLONE 4 MG DOSEPK
FDB brand name Methylprednisolone
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 045311
  • GCN: 37499
  • GPI-14 (Medi-Span): 2210003000B705
  • HICL (First Databank): 002877
  • AHFS class code: 68:04.00.00
  • RxCUI (RxNorm): 259966
Why two NDCs? The FDA registers this code as 68001-624-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 68001-0624-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids, potent (group III), Corticosteroids, weak (group I), Glucocorticoids
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name METHYLPREDNISOLONE 4 MG DOSEPK Ingredient Methylprednisolone
📗 Our plain-language guide HelloPharmacist
  • It is a steroid that calms inflammation and allergic reactions. Depending on the product, it is used for allergic conditions, skin diseases, adrenal gland problems, and (as tablets...
  • Take the tablets by mouth exactly as your prescriber directs. The dose depends on your condition and how you respond. Your prescriber may lower it step by step. Injections are give...
  • Steroids can increase appetite and weight, cause fluid retention, trouble sleeping, mood swings, acne, thin skin, and slower wound healing. Call your doctor if you notice signs of...
  • If you have taken it for a long time, do not stop suddenly. Steroids can suppress your body’s own steroid production, so your prescriber will lower the dose gradually.
📖 Read our full Methylprednisolone guide →
9
Nutrient depletion considerations

Methylprednisolone may be associated with lower levels of 9 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Methylprednisolone nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.136 $2.86 / 21 tablets
Medicaid paysCMS SDUD · 12 mo $0.5335 $11.20 / 21 tablets
Medicare drug plans payPart D · Q2 2026 $0.3466 $7.28 / 21 tablets
Medicare Part B allowsASP · J7509 $0.160 / J7509 unit —
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.136 $0.112
▲ Up 17% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)68001-624-01
11-digit billing NDC68001-0624-01
Format5-3-2 as registered → padded to 5-4-2 for billing (zero added to the product segment)
HCPCS J-codeJ7509
DescriptorMETHYLPREDNISOLONE ORAL, PER 4 MG
Billing units / pkg1 units
How the units are derivedThis package is 21 EA; the HCPCS unit is 4 MG, so one package = 1 billing unit.
Medicare Part B spend (2026 (Q1))$471 · 100 claims · $4.71 per claim (all NDCs under J7509)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
68001-0624-01 You're viewing this Main listing 1 BLISTER PACK in 1 CARTON / 21 TABLET in 1 BLISTER PACK Sample 2025-05-01 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
methylprednisolone 4 mg 00904-6914-61 Major 100 tablets $0.121 AB Availability likely save 11%
Methylprednisolone 4 mg 62135-0760-01 Chartwell 100 tablets $0.121 — Availability likely save 11%
methylprednisolone 4 mg 68382-0916-01 Zydus 100 tablets $0.121 AB Availability likely save 11%
Methylprednisolone 4 mg 68084-0149-01 American 100 tablets $0.121 AB Availability likely save 11%
Methylprednisolone 4 mg 42806-0400-01 Epic 100 tablets $0.124 AB Availability likely save 9%
Methylprednisolone 4 mg 59762-4440-02 Mylan 21 tablets $0.136 AB Availability likely —
methylprednisolone 4 mgthis 68001-0624-01 BluePoint 21 tablets $0.136 AB Availability likely —
MethylPREDNISolone 4 mg 00603-4593-15 Par 21 tablets $0.136 AB Availability likely —
Medrol 4 mg 00009-0056-02 Pharmacia 100 tablets $0.245 AB Availability likely +80%
Methylprednisolone 4 mg 69306-0400-21 Doc 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 71205-0453-21 Proficient 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 76420-0041-21 Asclemed 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 76420-0193-21 Asclemed 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 63187-0160-21 Proficient 21 tablets — AB FDA listed —
MethylPREDNISolone 4 mg 63629-2226-01 Bryant 21 tablets — AB FDA listed —
MethylPREDNISolone 4 mg 72162-1161-01 Bryant 100 tablets — AB FDA listed —
methylprednisolone 4 mg 82804-0007-21 Proficient 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 85509-1400-02 PHOENIX 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 68071-2370-01 NuCare 21 tablets — AB FDA listed —
MethylPREDNISolone 4 mg 63629-2218-01 Bryant 100 tablets — AB FDA listed —
Methylprednisolone 4 mg 85766-0037-01 Sportpharm 100 tablets — AB FDA listed —
Methylprednisolone 4 mg 80425-0230-01 Advanced 21 tablets — AB FDA listed —
methylprednisolone 4 mg 50090-3811-00 A-S 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 80425-0231-01 Advanced 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 80425-0255-01 Advanced 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 50090-3094-00 A-S 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 57582-0101-01 Tianjin 100 tablets — AB FDA listed —
Methylprednisolone 4 mg 68071-5221-01 NuCare 21 tablets — AB FDA listed —
methylprednisolone 4 mg 70771-1348-01 Zydus 100 tablets — AB FDA listed —
Methylprednisolone 4 mg 72189-0264-21 Direct_Rx 21 tablets — AB FDA listed —
MethylPREDNISolone 4 mg 55289-0649-30 PD-Rx 30 tablets — AB FDA listed —
Methylprednisolone 4 mg 68788-7833-02 Preferred 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 70518-2864-00 REMEDYREPACK 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 60760-0961-21 St. 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 70518-4213-00 REMEDYREPACK 21 tablets — AB FDA listed —
Methylprednisolone 4 mg 85534-0035-00 HAWAII 21 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2025
On the market since
May 2025
📍
2026
Currently FDA-listed
1 year listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeOval
Imprint916
Size8 mm
ScoringScored — splits in 4
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerBluePoint Laboratories
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA206751 (ANDA)
Labeler code68001
First marketedMay 2025
Product typeHuman Prescription Drug
Portfolio347 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 📚 References 📄 Package Label / Principal Display Panel
🎯 Indications and Usage ~2 min read ▾

INDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

⏱️ Dosage and Administration ~3 min read ▾

DOSAGE AND ADMINISTRATION The initial dosage of methylprednisolone tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted.

If after a reasonable period of time there is a lack of satisfactory clinical response, methylprednisolone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.

It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of methylprednisolone for a period of time consistent with the patient's condition.

If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. Multiple Sclerosis In treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective (4 mg of methylprednisolone is equivalent to 5 mg of prednisolone). ADT ® (Alternate Day Therapy) Alternate day therapy is a corticosteroid dosing regimen in which twice the usual daily dose of corticoid is administered every other morning.

The purpose of this mode of therapy is to provide the patient requiring long-term pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the Cushingoid state, corticoid withdrawal symptoms, and growth suppression in children. The rationale for this treatment schedule is based on two major premises: (a) the anti-inflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for reestablishment of more nearly normal hypothalamic-pituitary-adrenal (HPA) activity on the offsteroid day.

A brief review of the HPA physiology may be helpful in understanding this rationale. Acting primarily through the hypothalamus a fall in free cortisol stimulates the pituitary gland to produce increasing amounts of corticotropin (ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA system is characterized by diurnal (circadian) rhythm.

Serum levels of ACTH rise from a low point about 10 pm to a peak level about 6 am. Increasing levels of ACTH stimulate adrenal cortical activity resulting in a rise in plasma cortisol with maximal levels occurring between 2 am and 8 am. This rise in cortisol dampens ACTH production and in turn adrenal cortical activity.

There is a gradual fall in plasma corticoids during the day with lowest levels occurring about midnight. The diurnal rhythm of the HPA axis is lost in Cushing's disease, a syndrome of adrenal cortical hyperfunction characterized by obesity with centripetal fat distribution, thinning of the skin with easy bruisability, muscle wasting with weakness, hypertension, latent diabetes, osteoporosis, electrolyte imbalance, etc. The same… [Excerpted — this section continues on DailyMed.]

⛔ Contraindications 9 words ▾

CONTRAINDICATIONS Systemic fungal infections and known hypersensitivity to components.

⚠️ Warnings ~2 min read ▾

WARNINGS In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids including methylprednisolone suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan or helminthic pathogens. Corticosteroids can: Reduce resistance to new infections Exacerbate existing infections Increase the risk of disseminated infections Increase the risk of reactivation or exacerbation of latent infections Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal.

The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider methylprednisolone withdrawal or dosage reduction as needed. Tuberculosis If methylprednisolone is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur.

Closely monitor such patients for reactivation. During prolonged methylprednisolone therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including methylprednisolone.

In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles: If a methylprednisolone-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered. If a methylprednisolone-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.

Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including methylprednisolone. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with methylprednisolone.

For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy. Fungal Infections Corticosteroids, including methylprednisolone, may exacerbate systemic fungal infections; therefore, avoid methylprednisolone use in the presence of such infections unless methylprednisolone is needed to control drug reactions. For patients on chronic methylprednisolone therapy who develop systemic fungal infections, methylprednisolone withdrawal or dosage reduction is recommended.

Amebiasis Corticosteroids, including methylprednisolone, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating methylprednisolone in patients who have spent time in the tropics or patients with unexplained diarrhea. Strongyloides Infestation Corticosteroids, including methylprednisolone, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation.

In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Cerebral Malaria Avoid corticosteroids, including methylprednisolone, in patients with cerebral malaria. Ophthalmic Effects Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage… [Excerpted — this section continues on DailyMed.]

🤒 Adverse Reactions ~1 min read ▾

ADVERSE REACTIONS Fluid and Electrolyte Disturbances Sodium retention Congestive heart failure in susceptible patients Hypertension Fluid retention Potassium loss Hypokalemic alkalosis Musculoskeletal Muscle weakness Loss of muscle mass Steroid myopathy Osteoporosis Tendon rupture, particularly of the Achilles tendon Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal Peptic ulcer with possible perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT), and alkaline phosphatase have been observed following corticosteroid treatment.

These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation. Dermatologic Impaired wound healing Petechiae and ecchymoses May suppress reactions to skin tests Thin fragile skin Facial erythema Increased sweating Neurological Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment Convulsions Vertigo Headache Endocrine Development of Cushingoid state Suppression of growth in children Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness Menstrual irregularities Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements of insulin or oral hypoglycemic agents in diabetics Ophthalmic Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Exophthalmos Metabolic Negative nitrogen balance due to protein catabolism Vascular Flushing The following additional reactions have been reported following oral as well as parenteral therapy: Urticaria and other allergic, anaphylactic or hypersensitivity reactions.

🔄 Drug Interactions ~1 min read ▾

DRUG INTERACTIONS The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.

Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity.

Methylprednisolone may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.

The effect of methylprednisolone on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.

Information for the Patient Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.

📦 How Supplied / Storage and Handling 54 words ▾

HOW SUPPLIED Methylprednisolone tablets USP, 4 mg are white to off-white, oval-shaped, flat-faced, beveled-edge tablets, debossed with '916' on one side and quadrisect on other side and are supplied as follows: NDC 68001-624-01 in unit-of-use cartons of 21 tablets Store at 20°C to 25° C (68°F to 77° F) [See USP Controlled Room Temperature].

📋 Description 193 words ▾

DESCRIPTION Methylprednisolone tablets contain methylprednisolone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Methylprednisolone, USP occurs as a white to practically white, odorless, crystalline powder.

It melts at about 240°C, with some decomposition. It is practically insoluble in water, sparingly soluble in ethanol (96 %), in dioxane, in methanol and slightly soluble in acetone, in methylene chloride and in chloroform, very slightly soluble in ether. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11, 17, 21-trihydroxy-6-methyl-,(6α,11β)- and the molecular weight is 374.48.

The structural formula is represented below: C 22 H 30 O 5 Each methylprednisolone tablet USP, contains 4 mg of methylprednisolone. In addition each tablet contains the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, and sodium starch glycolate. ACTIONS Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states.

Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. methylpredisolone

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General Precautions Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis. Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation. The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis. Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed. Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease.

The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (see DOSAGE AND ADMINISTRATION.) Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used. In post marketing experience, tumor lysis syndrome (TLS) has been reported in patients with malignancies, including hematological malignancies and solid tumors, following the use of systemic corticosteroids alone or in combination with other chemotherapeutic agents.

Patients at high risk of TLS, such as patients with tumors that have a high proliferative rate, high tumor burden and high sensitivity to cytotoxic agents, should be monitored closely and appropriate precautions should be taken.

📚 References 95 words ▾

REFERENCES Fekety R. Infections associated with corticosteroids and immunosuppressive therapy. In: Gorbach SL, Bartlett JG, Blacklow NR, eds.

Infectious Diseases. Philadelphia: WBSaunders Company 1992:1050–1. Stuck AE, Minder CE, Frey FJ.

Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 1989:11(6):954–63. Call your doctor for medical advice about side effects.

You may report side effects to FDA at 1-800-FDA-1088. Please address medical inquiries to, ([email protected]) Tel.: 1-877-993-8779. This product's label may have been updated.

For current full prescribing information, please visit www.zydususa.com Manufactured by: Zydus Lifesciences Ltd. Ahmedabad, India For BluePoint Laboratories Rev.: 02/26

📄 Package Label / Principal Display Panel 106 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 68001-624-01 in unit-of-use cartons of 21 tablets Methylprednisolone tablets, USP- Carton R x only 21 tablets Carton Methylprednisolone Tabs USP 4 mg Carton - Methylprednisolne Tablets USP 4 mg Package/Label Display Panel NDC 68001-624-01 in unit-of-use cartons of 21 tablets Methylprednisolone tablets, USP- Lidding Foil and Forming Foil R x only 21 tablets Lidding Foil- Methylprednisolone Tablets USP 4MG Forming Foil- Methylprednisolone Tablets USP 4MG

Package/Label Display Panel NDC 68001-624-01 in unit-of-use cartons of 21 tablets Methylprednisolone tablets, USP- Lidding Foil and Forming Foil R x only 21 tablets Lidding Foil- Methylprednisolone Tablets USP 4MG Forming Foil- Methylprednisolone Tablets USP 4MG

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q2 2025 – Q1 2026 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
34.7K
Units reimbursed last 4 qtrs
720.9K
Gross reimbursed last 4 qtrs
$384.6K
Avg / prescription
$11.07
Avg / unit
$0.5335
Latest quarter Q1 2026
12.5KRx
Medicaid pays / ea
$0.5335
gross reimbursed
vs
NADAC / ea
$0.1361
acquisition cost
=
Spread
+$0.3974
+292% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
30% FFS 70% MCO
Fee-for-service · 10,321 Rx Managed care · 24,410 Rx
State Medicaid map
Alaska: no data reported AK Maine: 2,772 units · 199 per 100k residents ME Washington: 5,313 units · 68.0 per 100k residents WA Idaho: 5,754 units · 293 per 100k residents ID Montana: 1,092 units · 96.5 per 100k residents MT North Dakota: 3,213 units · 410 per 100k residents ND Minnesota: 5,901 units · 103 per 100k residents MN Wisconsin: 7,982 units · 135 per 100k residents WI Michigan: 35,752 units · 356 per 100k residents MI New York: 23,448 units · 120 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 3,934 units · 92.9 per 100k residents OR Nevada: 4,149 units · 130 per 100k residents NV Wyoming: 546 units · 93.5 per 100k residents WY South Dakota: 945 units · 103 per 100k residents SD Iowa: 6,031 units · 188 per 100k residents IA Illinois: 18,930 units · 151 per 100k residents IL Indiana: 14,947 units · 218 per 100k residents IN Ohio: 43,045 units · 365 per 100k residents OH Pennsylvania: 32,178 units · 248 per 100k residents PA New Jersey: 22,140 units · 238 per 100k residents NJ Massachusetts: 3,507 units · 50.1 per 100k residents MA California: 25,599 units · 65.7 per 100k residents CA Utah: 2,235 units · 65.4 per 100k residents UT Colorado: 6,594 units · 112 per 100k residents CO Nebraska: 3,003 units · 152 per 100k residents NE Missouri: 27,341 units · 441 per 100k residents MO Kentucky: 151,236 units · 3,341 per 100k residents KY West Virginia: 34,818 units · 1,967 per 100k residents WV Virginia: 14,953 units · 172 per 100k residents VA Maryland: 6,217 units · 101 per 100k residents MD Connecticut: 4,064 units · 112 per 100k residents CT Rhode Island: 1,113 units · 102 per 100k residents RI Arizona: 1,638 units · 22.0 per 100k residents AZ New Mexico: 10,321 units · 488 per 100k residents NM Kansas: 6,002 units · 204 per 100k residents KS Arkansas: 27,804 units · 907 per 100k residents AR Tennessee: 12,289 units · 172 per 100k residents TN North Carolina: 25,035 units · 231 per 100k residents NC South Carolina: 13,057 units · 243 per 100k residents SC Delaware: no data reported DE Oklahoma: 17,472 units · 431 per 100k residents OK Louisiana: 21,441 units · 469 per 100k residents LA Mississippi: 12,812 units · 436 per 100k residents MS Alabama: 6,354 units · 124 per 100k residents AL Georgia: 25,019 units · 227 per 100k residents GA D.C.: no data reported DC Hawaii: 1,428 units · 99.5 per 100k residents HI Texas: 12,806 units · 42.0 per 100k residents TX Florida: 8,717 units · 38.6 per 100k residents FL
Units reimbursed · per 100k residents
22.03,341
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 3,341 /100k
2 West Virginia 1,967 /100k
3 Arkansas 907 /100k
4 New Mexico 488 /100k
5 Louisiana 469 /100k
6 Missouri 441 /100k
7 Mississippi 436 /100k
8 Oklahoma 431 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Methylprednisolone — the program that covers self-administered drugs. 9 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Methylprednisolone. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$11.32M
Claims incl. refills
1.6M
Beneficiaries
1.4M
Spend / beneficiary
$7.99
Spend / claim
$7.26
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 68001-0623-04 · BluePoint 68001-0625-93 · BluePoint →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.